Ventana CEO Headlines Congressional Briefing on Patient Safety and Cancer

  Ventana CEO Headlines Congressional Briefing on Patient Safety and Cancer

Often-overlooked patient safety risks in medical laboratories take center
stage in effort to continue to improve US standards

PR Newswire

TUCSON, Ariz., Nov. 19, 2012

TUCSON, Ariz., Nov. 19, 2012 /PRNewswire/ -- Ventana Medical Systems, Inc.
(Ventana), a member of the Roche Group, announced that a Congressional
Briefing in Washington this week explored critical patient safety issues
related to tissue slide processing that often get overlooked in US clinical
and anatomic laboratories. Some of the most acute risk areas include patient
specimen misidentification and cross-contamination―areas that many deem
serious enough to warrant future reform of lab industry standards in an effort
to better protect patients.

To view the multimedia assets associated with this release, please click
http://www.prnewswire.com/news-releases/ventana-ceo-headlines-congressional-briefing-on-patient-safety-and-cancer-179971531.html

The Briefing, entitled "A Dialogue on Patient Safety and Cancer," was designed
to educate federal legislators and their staffs about patient safety issues as
they consider related legislation, regulatory oversight, and constituent
service in the future.

Rep. Ron Barber delivered opening remarks for the company-sponsored Briefing
before introducing Mara G. Aspinall, President, Ventana Medical Systems, Inc.
Aspinall moderated a distinguished panel including Maurie Markman, MD, Senior
Vice President of Clinical Affairs/National Director of Medical Oncology,
Cancer Treatment Centers of America; Eric Walk, MD, FCAP, Senior Vice
President, Medical & Scientific Affairs, Ventana; and Patricia McGaffigan, RN,
MS, Interim President National Patient Safety Foundation.

"In line with our mission, 'to improve the lives of all patients afflicted
with cancer,' we were very pleased to sponsor this Congressional Briefing to
educate federal legislators and their staffs about critical patient safety
issues not uncommon in today's labs," said Aspinall. "Understanding these
issues is a vital first step for those considering legislation that could
reduce risk and improve US patient safety practices moving forward."

Senior health and science aides for members of Congress; key congressional
committee staff; executives from a wide range of professional and trade
associations involved in health care delivery, medical research and medical
technology; and representatives of the broad cancer community attended this
first-of-its kind briefing event.

"Patient safety is an essential attribute of quality care and an ethical and
moral imperative. We have an obligation to our patients, their caregivers and
one another to protect against errors or failures," said Maurie Markman. "At
Cancer Treatment Center of America®, there is no priority higher than patient
safety. If there is a conflict between safe practice and speed, efficiency or
patient satisfaction, patient safety will always win – it is a critical part
of the patient experience which places the patient and his/her well-being at
the center of everything we do."

More information about patient safety in the lab can be found at the Ventana
sponsored website SaferPath.org.

About Ventana Medical Systems, Inc.
Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member
of the Roche Group, innovates and manufactures instruments and reagents that
automate tissue processing and slide staining for cancer diagnostics. VENTANA
solutions are used in clinical histology and drug development research
laboratories worldwide. The company's intuitive, integrated staining, workflow
management platforms, and digital pathology solutions optimize laboratory
efficiencies to reduce errors, support diagnosis and inform treatment
decisions for anatomic pathology professionals. Together with Roche, VMSI is
driving Personalized Healthcare through accelerated drug discovery and the
development of "companion diagnostics" to identify the patients most likely to
respond favorably to specific therapies. VENTANA and the VENTANA logo are
trademarks of Roche.
Visit www.ventana.com to learn more.



VMSI Media Relations
Jacqueline Bucher
Senior Director, Corporate Communications
Phone: 520-877-7288
e-mail: jacquie.bucher@ventana.roche.com

SOURCE Ventana Medical Systems, Inc.

Website: http://www.ventana.com